Lumos Pharma Statistics

Total Valuation

Lumos Pharma has a market cap or net worth of $37.54 million. The enterprise value is $24.19 million.

Market Cap	37.54M
Enterprise Value	24.19M

Important Dates

The last earnings date was Thursday, November 7, 2024.

Earnings Date	Nov 7, 2024
Ex-Dividend Date	n/a

Share Statistics

Lumos Pharma has 8.65 million shares outstanding. The number of shares has decreased by -0.71% in one year.

Current Share Class	8.65M
Shares Outstanding	8.65M
Shares Change (YoY)	-0.71%
Shares Change (QoQ)	+2.65%
Owned by Insiders (%)	13.90%
Owned by Institutions (%)	24.15%
Float	5.84M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	16.06
Forward PS	n/a
PB Ratio	7.64
P/TBV Ratio	7.64
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	10.97
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.66, with a Debt / Equity ratio of 0.04.

Current Ratio	2.66
Quick Ratio	2.11
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -172.83% and return on invested capital (ROIC) is -111.17%.

Return on Equity (ROE)	-172.83%
Return on Assets (ROA)	-69.64%
Return on Capital (ROIC)	-111.17%
Revenue Per Employee	$66,818
Profits Per Employee	-$1.06M
Employee Count	33
Asset Turnover	0.07
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +48.63% in the last 52 weeks. The beta is 0.31, so Lumos Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.31
52-Week Price Change	+48.63%
50-Day Moving Average	4.20
200-Day Moving Average	3.09
Relative Strength Index (RSI)	55.58
Average Volume (20 Days)	132,961

Short Selling Information

The latest short interest is 54,328, so 0.63% of the outstanding shares have been sold short.

Short Interest	54,328
Short Previous Month	89,511
Short % of Shares Out	0.63%
Short % of Float	0.93%
Short Ratio (days to cover)	0.59

Income Statement

In the last 12 months, Lumos Pharma had revenue of $2.21 million and -$34.92 million in losses. Loss per share was -$4.28.

Revenue	2.21M
Gross Profit	2.21M
Operating Income	-36.33M
Pretax Income	-35.75M
Net Income	-34.92M
EBITDA	-36.31M
EBIT	-36.33M
Loss Per Share	-$4.28

Full Income Statement

Balance Sheet

The company has $13.52 million in cash and $172,000 in debt, giving a net cash position of $13.35 million or $1.54 per share.

Cash & Cash Equivalents	13.52M
Total Debt	172,000
Net Cash	13.35M
Net Cash Per Share	$1.54
Equity (Book Value)	4.91M
Book Value Per Share	0.57
Working Capital	10.77M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-31.67M
Capital Expenditures	n/a
Free Cash Flow	-31.67M
FCF Per Share	-$3.66

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-1,647.57%
Pretax Margin	-1,583.49%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-2,320.79%

Dividends & Yields

Lumos Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.71%
Shareholder Yield	0.71%
Earnings Yield	-93.02%
FCF Yield	-84.38%

Analyst Forecast

The average price target for Lumos Pharma is $9.38, which is 116.13% higher than the current price. The consensus rating is "Buy".

Price Target	$9.38
Price Target Difference	116.13%
Analyst Consensus	Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	37.55%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Lumos Pharma has an Altman Z-Score of -19.87 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-19.87
Piotroski F-Score	2